Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Quintiles Group Makes Bio-Investment | Contract Pharma

What are you searching for?

Sign in
Breaking News

Quintiles Group Makes Bio-Investment

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

NovaQuest, the strategic partnering group of Quintiles Transnational, has made a strategic investment in Topigen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in respiratory disorders.  The investment, part of a private placement of $25 million in the Montreal-based company, is intended to helps Topigen accelerate its Phase II lead-product clinical programs.  NovaQuest and Quintiles first provided strategic product development advice to the company three years ago, and the relationship has since evolved into an integrated development partnership.

Patricia Lamothe, Topigen’s chief financial officer, said, “The ability to access NovaQuest’s clinical expertise and Quintiles’ development capabilities is a tremendous benefit to our company as we continue to advance our product candidates for significant breakthroughs in the treatment of respiratory diseases.”

NovaQuest vice president Ben Cons, Ph.D., added, “Having been very active in 2006, with 16 strategic investments, our focus now is to create fewer but larger partnerships.  We’re seeking high potential biotechs — those with excellent pipelines and strong management teams.”

In November NovaQuest made a strategic investment in Canadian biotech company BioMS Medical Corp., a developer of treatments for multiple sclerosis.  For all of 2006, NovaQuest participated as a minority investor in funding rounds that raised a total of $342 million for 16 emerging biotechnology companies worldwide.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters